Log In
Print
BCIQ
Print
Print this Print this
 

INN-329 (formerly RG1068, SecreFlo)

Also known as: secretin

  Manage Alerts
Collapse Summary General Information
Company Innovate Biopharmaceuticals Inc.
DescriptionSynthetic human secretin
Molecular Target Unknown
Mechanism of ActionDiagnostic; Unknown
Therapeutic ModalityDiagnostics
Latest Stage of DevelopmentPhase III
Standard IndicationGastrointestinal, Diagnostic
Indication DetailsAid in functional MRI of the pancreas; Help in the location and cannulation of the minor pancreatic duct in patients with pancreas divisum; Improve detection and characterization of pancreatic cancer in combination with MRI; Improve detection of pancreatic duct abnormalities in combination with MRI; Improve detection of structural abnormalities of the pancreatic ducts during magnetic resonance imaging (MRI); Stimulate pancreatic secretions to aid in diagnosis of pancreatic exocrine dysfunction
Regulatory Designation

U.S. - Fast Track (Improve detection of structural abnormalities of the pancreatic ducts during magnetic resonance imaging (MRI));
U.S. - Orphan Drug (Improve detection of structural abnormalities of the pancreatic ducts during magnetic resonance imaging (MRI));
U.S. - Priority Review (Improve detection of structural abnormalities of the pancreatic ducts during magnetic resonance imaging (MRI))

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today